Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors

Steroids

Volumn 76, Issue 8, 2011, Pages 750-752

  Ma, Cynthia X ^a,b   Crowder, Robert J ^b   Ellis, Matthew J ^a,b  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Endocrine therapy; Phosphatidylinositol 3 kinase (PI3K)

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; AEW 541; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; EVEROLIMUS; GROWTH DIFFERENTIATION FACTOR 15; KI 67 ANTIGEN; LETROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA CATALYTIC SUBUNIT; PHOSPHATIDYLINOSITOL 3 KINASE BETA CATALYTIC SUBUNIT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 SUBSTRATE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE P60; PROTEIN P110 ALPHA; PROTEIN P110 BETA; S6 PROTEIN KINASE 1; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; CELL TRANSFORMATION; CONFERENCE PAPER; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; ENZYME SUBUNIT; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EXON; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC REGULATION; HORMONE RESISTANCE; HUMAN; LOSS OF FUNCTION MUTATION; PROGNOSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; UPREGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 79958770468     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.023     Document Type: Conference Paper

References (33)

1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(July):489-501. (Pubitemid 37328931)
2. Crowder RJ, Ellis MJ. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3′-kinase pathway. Breast Cancer Res 2005;7:212-4. (Pubitemid 41387433)
3. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24(November):7455-64. (Pubitemid 41637985)
4. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207(October):139-46. (Pubitemid 41404144)
5. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010;119(January):379-90.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304(April):554. (Pubitemid 38541907)
7. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65(April):2554-9. (Pubitemid 40490050)
8. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448(July):439-44. (Pubitemid 47123510)
9. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68(August):6084-91.
10. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008;98(May):1533-5. (Pubitemid 351652321)
11. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009;69(May):3955-62.
12. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64(August):280-5.
13. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(March):1943-7. (Pubitemid 27148818)
14. Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 2000;60(October):5340-4.
15. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14(July):672-6. (Pubitemid 32667211)
16. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009;15(August):5049-59.
17. Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, Wu G. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat 2008;112(November):217-27.
18. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005;102(December):18443- 8. (Pubitemid 43011245)
19. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16(July):21-32.
20. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, et al. PTEN-deficient cancers depend on PIK3C.B. Proc Natl Acad Sci USA 2008;105(September):13057-62.
21. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96(March):91-5.
22. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007;13(January):408-14. (Pubitemid 46225343)
23. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007;13(June):3577-84. (Pubitemid 46955118)
24. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible akt activity promotes resistance to chemotherapy trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1(July):707-17.
25. Faridi J, Wang L, Endemann G, Roth RA. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 2003;9(August):2933-9. (Pubitemid 36993252)
26. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276(March):9817-24.
27. Farmer I, Evans DB, Lane HA, Lykkesfeldt AE, Dowsett M, Martin L-A. Combination approach using RAD001 plus or minus tamoxifen or letrozole A preclinical model of the treatment of endocrine-resistant breast tumours. In: SABCS, abstract # 4084. 2005.
28. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004;10(December):8059-67.
29. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004;15(October):1510-6. (Pubitemid 39409742)
30. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11(July):5319-28. (Pubitemid 41003721)
31. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, deGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18(August):1323-8.
32. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120(July):2406-13.
33. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006;66(April):3903-11.